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Abstract 
Joint replacement surgery is a standard treatment of advanced osteoarthritis (OA). Since 2000, cobalt-
chromium (CoCr) metal-on-metal (MoM) implants were widely used in hip arthroplasties. Some patients 
developed “adverse reaction to metal debris” (ARMD) around the prosthesis resulting in a need for revision 
surgery. In the present study, we addressed the pathogenesis of ARMD by genome-wide expression analysis.  
Pseudosynovial ARMD tissue was obtained from revision surgery of Articular Surface Replacement (ASR, 
DePuy, Warsaw, IN, USA) hip arthroplasties. Control tissue was 1) OA synovium from primary hip 
arthroplasties and 2) inflammatory pseudosynovial tissue from metal-on-plastic (MoP) implant revisions.   
In ARMD tissue, the expression of 1446 genes was significantly increased and that of 1881 decreased as 
compared to OA synovium. Genes associated with immune response, tissue development and certain 
leukocyte signaling pathways were enriched in the differently (FC >2) expressed genes. The network analysis 
proposed PRKACB, CD2, CD52 and CD53 as the central regulators of the greatest (FC >10) differences.  
When ARMD tissue was compared to MoP tissue, the expression of 16 genes was significantly higher and 
that of 21 lower. Many of these genes were associated with redox homeostasis, metal ion binding and 
transport, macrophage activation and apoptosis. Interestingly, genes central to myofibroblast (AEBP1 and 
DES) and osteoclast (CCL21, TREM2 and CKB) development were upregulated in the MoP tissue. In network 
analysis, IL8, NQO1, GSTT1 and HMOX1 were identified as potential central regulators of the changes. 
In conclusion, excessive amounts of CoCr debris produced by MoM hip implants induces in a group of patients 
a unique adverse reaction characterized with enhanced expression of genes associated with inflammation, 
redox homeostasis, metal ion binding and transport, macrophage activation and apoptosis.  
 
Keywords: joint replacement; adverse reaction to metal debris; metal-on-metal implant; metal-on-plastic 
implant; RNA-Seq  
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Introduction 
Total hip joint replacement surgery is a standard treatment for advanced osteoarthritis (OA), rheumatoid 
arthritis (RA) and hip fracture [1–3]. During the first decade of the 21st century, metal-on-metal (MoM) 
implants were widely used in these operations, aiming at increased mechanical durability compared to the 
conventional metal-on-plastic (MoP) implants [4,5]. However, a part of the patients developed adverse 
inflammatory reactions around the implant, requiring revision surgery. Named “adverse reaction to metal 
debris” (ARMD), these reactions are characterized by marked inflammation and, in some cases, pseudotumor 
formation [6,7]. 
The ARMD reaction is thought to be caused by metal, especially cobalt, ions and nanoparticles abraded from 
the implant [8,9], but the detailed pathogenesis of the reaction remains unknown. However, it has been 
shown to include systemic dissemination of metal ions and nanoparticles, increased oxidative stress, 
inflammation, DNA damage and coagulative necrosis [10–12]. 
Lymphocytes and macrophages are predominant cell types in ARMD reaction [6,13]. Metal ions may act as 
haptens, activating T cells and eliciting a delayed hypersensitivity reaction (type IV immune response) [14]. 
Their direct cytotoxic effects can also cause tissue necrosis, which in turn may attract macrophages and lead 
to granulomatous responses [15] and osteolysis [16]. Cobalt may also stimulate macrophages through direct 
activation of Toll-like receptor 4 (TLR4) [17] and/or so-called danger signaling [18]. 
Reactions observed around a failed MoP implants share many features of the ARMD reaction. They are 
characterized by lymphocytic inflammation [19], macrophage activation, differentiation of mononuclear cells 
into osteoclasts and subsequent osteolysis [20]. These reactions are thought to be driven by implant-derived 
polyethylene particles [21], which can elicit inflammation and osteolysis in in vitro models [22]. 
In the present study, we approached the pathogenesis of the ARMD reaction by genome-wide expression 
analysis, with a special focus on differences between ARMD tissue and the inflammatory response around 
failed MoP joints. 
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Materials and methods 
Patients 
The study was approved by the Ethics Committee of Tampere University Hospital, Tampere, Finland, and 
complies with the declaration of Helsinki. All patients provided their written informed consent. Pseudotumor 
tissue from ten revision surgeries of Articular Surface Replacement (ASR) XL hip implants (DePuy, Warsaw, 
IN, USA) were collected and analyzed. Control samples of pseudosynovial tissue were collected from six 
revision operations of failed metal-on-plastic (MoP) joints and synovial samples from five OA patients in 
primary total hip arthroplasties. All operations were carried out at Coxa Hospital for Joint Replacement, 
Tampere, Finland, and all primary arthroplasties had been performed for the treatment of end-stage 
osteoarthritis. 
Reasons for Revision Surgery 
Revision surgeries of MoM hips were performed for one (or more) of the following indications:  
1) a pseudotumour, either with a solid core or atypical contents, was seen in the vicinity of the implant, 
regardless of symptoms and whole blood metal ion levels; or 2) the patient had both elevated metal ion 
levels and hip symptoms despite a normal finding on cross-sectional imaging; or 3) the patient had an 
increasingly and significantly symptomatic hip regardless of imaging findings or metal ion levels. Symptoms 
included hip pain, discomfort, sense of instability, and/or impaired function of the hip as well as sounds from 
the hip. Infection was ruled out by at least five bacterial cultures obtained during revision surgery. The 
revision surgeries of MoP hips were performed for either aseptic loosening of the implants or for recurrent 
dislocation of the hip. The MoP implants included various brands and had been in-situ for a minimum of one 
year. 
Tissue processing and RNA extraction 
Peri-implant tissue was obtained directly from surgery. Necrotic mass (if present) was removed, and the 
tissue was cut into pieces weighing approximately 100 mg and the tissue samples were stored in 1000 µl of 
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RNAlaterTM solution (Thermo Fisher Scientific, Waltham, MA, USA). The samples were centrifuged, 
supernatant removed, and the samples were homogenized in QIAshredderTM columns (Qiagen). Total RNA 
was extracted using RNeasy Mini Spin columns (Qiagen) and treated with DNAse (Fermentas UAB, Vilnius, 
Lithuania). 
Next-generation sequencing and data analysis 
Sequencing of the RNA samples was performed in the Turku Centre of Biotechnology sequencing core, Turku, 
Finland, using the Illumina HiSeq 2500 sequencing platform. Sequencing depth was 20 million single-end 
reads with length of 50 base pairs (bp). The data was analyzed using the automated TRAPLINE RNA-Seq data 
analysis workflow [23] implemented on the Galaxy platform [24]. In brief, the reads were trimmed for quality, 
and read quality was assessed using FastQC [25]. The reads were aligned to a reference human genome using 
TopHat2 [26], and differential expression was assessed with Cufflinks [27]. For the purposes of further 
analysis, genes with an expression fold change (FC) > 2.0 in either direction and false discovery rate (FDR)-
corrected p-value < 0.05 were deemed biologically and statistically significant. Functions of the genes were 
obtained from the NCBI Gene database, if not otherwise indicated. Mean gene expression levels are reported 
as reads per kilobase per million (RPKM) values. Functional analysis from the Gene Ontology (GO) database 
[28] was performed using the DAVID tool [29], and the resulting list was reduced using REVIGO [30]. Protein 
interactions were studied with STRING [31]. 
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Results 
When comparing ARMD tissue to OA tissue, the expression of 1446 genes was found to be significantly higher 
and that of 1881 genes significantly lower in the former. Of these, 622 genes had a positive expression fold 
change (FC) of more than 2.0, and 528 a negative one of similar magnitude. Tables 1 and 2 show 20 genes 
with the greatest FCs into both directions, along with their functions potentially relevant for the metal debris-
induced reaction. These can be seen to encompass a wide variety of different actions, especially lymphocyte 
and macrophage-mediated inflammatory response, tissue development, redox homeostasis and cellular 
metabolism. 
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Table 1: 20 genes with the highest expression levels in ARMD compared to OA tissue. Gene expression 
levels in adverse reaction to metal debris (ARMD) and osteoarthritis (OA) samples are listed as reads per 
kilobase million (RPKM) values, and the differences as fold changes (FCs). p-values are adjusted by false 
discovery rate (FDR). 
 
Gene Name Function RPKM (ARMD) RPKM (OA) FC adj. p 
TNFRSF14 
TNF receptor superfamily 
member 14 T-cell mediated immunity 61.09 0.20 307.19 0.0018 
FAM213B 
Family with sequence 
similarity 213 member B Prostaglandin synthesis 271.81 1.14 239.05 0.00043 
KCNAB2 
Potassium voltage-gated 
channel subfamily A 
regulatory beta subunit 2  Potassium transport 18.57 0.10 184.80 0.042 
PGD 
Phosphogluconate 
dehydrogenase Pentose phosphate shunt 33.22 0.22 153.04 0.014 
PEX14 
Peroxisomal biogenesis 
factor 14 Peroxisome production 3452.48 42.31 81.59 0.00043 
AGTRAP 
Angiotensin II receptor 
associated protein  
Regulation of vascular 
tone 187.96 2.44 77.09 0.00043 
MIIP 
Migration and invasion 
inhibitory protein 
Regulation of cell 
migration 16.12 0.24 66.56 0.00043 
TMEM51 Transmembrane protein 51 Membrane component 54.35 0.96 56.90 0.00043 
EFHD2 
EF-hand domain family 
member D2 
Regulation of cell 
migration 48.94 0.88 55.36 0.00043 
PLEKHM2 
Pleckstrin homology and 
RUN domain containing M2 Organelle localization 128.21 2.63 48.69 0.00043 
NECAP2 
NECAP endocytosis 
associated 2 Endocytosis 45.97 0.99 46.31 0.00043 
ARHGEF10L 
Rho guanine nucleotide 
exchange factor 10 like Signal transduction 55.92 1.37 40.81 0.00043 
C1QA Complement C1q A chain Innate immunity 16.80 0.43 38.84 0.00043 
PITHD1 PITH domain containing 1 
Regulation of gene 
expression 1916.92 54.85 34.95 0.00043 
LYPLA2 Lysophospholipase II Lipid metabolism 20.83 0.60 34.93 0.0024 
SH3BGRL3 
SH3 domain binding 
glutamate rich protein like 3 Redox homeostasis 43.63 1.30 33.68 0.00043 
CD52 CD52 molecule 
Respiratory burst, T cell 
receptor signaling 19.91 0.60 32.93 0.00043 
ZDHHC18 
Zinc finger DHHC-type 
containing 18 
Posttranslational 
modification 15.60 0.49 32.09 0.00043 
SYTL1 Synaptotagmin like 1  Exocytosis 4043.20 137.35 29.44 0.00043 
RAB42 
RAB42, member RAS 
oncogene family 
GTPase activity, GTP 
binding 11.91 0.44 27.17 0.0069 
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Table 2: 20 genes with the lowest expression levels in ARMD compared to OA tissue. Gene expression levels 
in adverse reaction to metal debris (ARMD) and osteoarhtritis (OA) samples are listed as reads per kilobase 
million (RPKM) values, and the differences as fold changes (FCs). p-values are adjusted by false discovery rate 
(FDR). 
Gene Name Function 
RPKM 
(ARMD) 
RPKM 
(OA) FC adj. p 
UCK2 Uridine-cytidine kinase 2 Pyrimidine metabolism 4.66 1387.25 -297.99 0.00043 
GDF5 Growth differentiation factor 5 Bone and cartilage development 0.15 19.56 -131.23 0.014 
GPD1 
Glycerol-3-phosphate 
dehydrogenase 1 
Carbohydrate and lipid 
metabolism 0.18 22.04 -122.14 0.00043 
ADH1B 
Alcohol dehydrogenase 1B 
(class I), beta polypeptide Alcohol metabolism 0.22 21.45 -98.64 0.00043 
SCUBE1 
Signal peptide, CUB domain 
and EGF like domain containing 
1  Thrombosis and inflammation 0.22 14.25 -63.50 0.0008 
TMEM196 Transmembrane protein 196 Regulation of cell proliferation 0.41 17.98 -43.38 0.00043 
SCRG1 Stimulator of chondrogenesis 1 Chondrogenesis 6.64 268.27 -40.39 0.00043 
NTRK2 
Neurotrophic receptor tyrosine 
kinase 2 Neuron development 0.63 20.82 -32.81 0.00043 
AMTN Amelotin Cell adhesion 3.89 123.23 -31.67 0.00043 
SEMA3A Semaphorin 3A Inhibition of angiogenesis 0.48 13.97 -28.96 0.00043 
ZNF385B Zinc finger protein 385B Apoptosis 1.01 28.69 -28.48 0.00043 
FGF10 Fibroblast growth factor 10 Skeletal system development 1.94 53.45 -27.57 0.00043 
DLX4 Distal-less homeobox 4  Regulation of transcription 0.94 25.10 -26.79 0.00739 
GPR1 G protein-coupled receptor 1 
G protein coupled receptor 
activity 2.34 58.64 -25.08 0.00043 
CA9 Carbonic anhydrase 9 Cell proliferation 2.30 56.10 -24.35 0.00043 
SLPI 
Secretory leukocyte peptidase 
inhibitor Immune response 9.51 222.85 -23.43 0.00043 
CLIC5 Chloride intracellular channel 5 Chloride transport 1.58 35.39 -22.34 0.00043 
SMOC1 
SPARC related modular calcium 
binding 1 Skeletal system development 3.06 62.38 -20.38 0.00043 
STAC2 SH3 and cysteine rich domain 2 Metal ion binding 0.54 10.61 -19.76 0.00043 
SGCA Sarcoglycan alpha Muscle development 1.23 23.14 -18.82 0.0008 
DLX3 Distal-less homeobox 3 Blood vessel development 1.20 21.90 -18.31 0.00043 
RASD1 
Ras related dexamethasone 
induced 1 Regulation of cell proliferation 4.38 79.12 -18.08 0.00043 
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When functions of the genes with FC > 2.0 were studied using the GO database (Table 3), functional 
categories involved immune response, macrophage and lymphocyte activation, cell adhesion, skeletal system 
development and several leukocyte signaling pathways (such as PI3KR1, phospholipase C, tyrosine kinase and 
integrin signaling). Additionally, Table 4 shows significant inflammatory and hypoxia-related genes which 
were expressed at higher level in ARMD than OA tissue. 
When interactions between the most strongly up- and downregulated (FC > 10) genes were investigated, 
PRKACB, CD2, CD52 and CD53 were identified as potential central regulators of the observed changes in gene 
expression. The interaction network also contained the immunoglobulin receptor genes FCGR2A, FCGF2B 
and FCER1G. Another, smaller network was centered on the pentose phosphate shunt -related gene 
phosphogluconate dehydrogenase (PGD), and yet another on aggrecan (ACAN) (Figure 1). 
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Table 3: GO terms covering genes with significantly altered expression in ARMD vs OA tissue. Genes with 
an expression fold change (FC) > 2.0 in either direction were studied with the DAVID tool using the Gene 
Ontology (GO) database, and the resulting list of terms was reduced with REVIGO. p-values are corrected by 
false discovery rate (FDR). 
Term 
Number of 
altered 
genes 
Total number 
of genes in 
the term adj. p 
Inflammatory response 110 407 6.74E-21 
Cell adhesion 117 751 1.21E-17 
Signal transduction 199 4491 2.30E-10 
Adaptive immune response 43 194 4.68E-07 
Cell-cell signaling 59 338 5.94E-06 
Cell surface receptor signaling pathway 62 1997 8.90E-06 
T cell costimulation 28 73 1.09E-05 
Integrin-mediated signaling pathway 32 77 1.33E-05 
Positive regulation of protein kinase B signaling 29 89 1.50E-05 
Negative chemotaxis 17 34 9.47E-05 
Transmembrane receptor protein tyrosine kinase signaling 
pathway 30 481 9.88E-05 
Extracellular matrix organization 47 292 0.0001 
Response to lipopolysaccharide 35 260 0.00025 
Positive regulation of GTPase activity 98 629 0.00035 
Negative regulation of axon extension involved in axon 
guidance 14 230 0.00071 
Aging 46 291 0.00097 
Positive regulation of interleukin-1 beta secretion 13 26 0.0011 
Positive chemotaxis 16 33 0.0011 
Positive regulation of cytosolic calcium ion concentration 35 235 0.0024 
Cellular defense response 21 56 0.0027 
Semaphorin-plexin signaling pathway 15 22 0.0031 
Positive regulation of cell proliferation 81 832 0.015 
Angiogenesis 46 245 0.016 
Positive regulation of peptidyl-tyrosine phosphorylation 24 166 0.023 
Platelet activation 29 108 0.023 
Leukocyte migration 30 284 0.026 
Proton transport 17 130 0.032 
Cellular response to interleukin-1 23 67 0.033 
Positive regulation of phosphatidylinositol 3-kinase signaling 20 64 0.033 
Skeletal system development 32 155 0.038 
Activation of phospholipase C activity 12 25 0.043 
Protein localization to cell surface 11 23 0.0478 
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Table 4: Inflammatory and hypoxia-related genes with higher expression in ARMD compared to OA tissue. 
Gene expression levels are listed as reads per kilobase million (RPKM) values, and the differences as fold 
changes (FCs). p-values are adjusted by false discovery rate (FDR). 
Gene Name Function RPKM (ARMD) 
RPKM 
(OA) FC adj. p 
Inflammatory genes 
S100A9 S100 calcium binding protein A9 Innate immunity 662.78 42.13 15.73 0.00043 
FCGR2B Fc fragment of IgG receptor IIb  Adaptive immune response 17.80 1.30 13.67 0.00043 
IL2RA Interleukin 2 receptor subunit alpha  Lymphocyte activation 10.14 1.55 6.54 0.00043 
IL18 Interleukin 18 Immune response 118.70 27.13 4.37 0.00043 
TNFSF13B TNF superfamily member 13b 
Lymphocyte proliferation and 
activation 17.14 4.74 3.62 0.00043 
SPN Sialophorin T cell activation 38.79 12.96 2.99 0.00043 
IRF8 interferon regulatory factor 8 Interferon-mediated immune response 16.00 5.49 2.91 0.00043 
CCL2 C-C motif chemokine ligand 2 Inflammation, monocyte chemotaxis 16.61 6.07 2.74 0.00043 
CCL13 C-C motif chemokine ligand 13 Lymphocyte and monocyte chemotaxis 27.02 9.93 2.72 0.00043 
CCL18 C-C motif chemokine ligand 18 Lymphocyte chemotaxis 137.69 50.68 2.72 0.00043 
CCR7 C-C motif chemokine receptor 7 Leukocyte activation and chemotaxis 18.95 7.31 2.59 0.00043 
CD7 CD7 molecule Lymphocyte activation 11.12 4.45 2.50 0.00043 
IL27RA Interleukin 27 receptor subunit alpha T cell activation 9.18 3.86 2.38 0.00043 
FCAR Fc fragment of IgA receptor  IgA-mediated immunity 10.28 4.50 2.29 0.00043 
TNFSF14 TNF superfamily member 14 T cell activation 68.91 30.37 2.27 0.00043 
ZAP70 
Zeta chain of T cell receptor 
associated protein kinase 70 Lymphocyte activation 133.38 62.73 2.13 0.00043 
CD8A CD8a molecule Tc cell activation 31.41 15.10 2.08 0.0083 
CD8B CD8b molecule Tc cell activation 22.48 10.82 2.08 0.00043 
IL1B Interleukin 1 beta Systemic inflammation 60.34 29.12 2.07 0.00043 
CD40 CD40 molecule Lymphocyte activation 16.37 8.06 2.03 0.00043 
Hypoxia-related genes 
HMOX1 Heme oxygenase 1 Widespread response to hypoxia 523.17 72.32 7.17 0.00043 
GSTO1 Glutathione S-transferase omega 1 Prevention of oxidative injury 411.06 60.58 6.79 0.00043 
ASCL2 
Achaete-scute family bHLH 
transcription factor 2 Response to hypoxia, HIF1A pathway 327.59 68.85 4.76 0.00043 
TXNRD1 Thioredoxin reductase 1 
Prevention of oxidative injury, Nrf2 
pathway 84.50 20.76 4.07 0.00043 
PRKCB Protein kinase C beta Response to hypoxia 26.71 8.82 3.03 0.00043 
EGLN3 
Egl-9 family hypoxia inducible factor 
3 
Apoptosis, regulation of cell 
proliferation 31.72 11.33 2.81 0.00043 
NQO1 NAD(P)H quinone dehydrogenase 1 Redox homeostasis, NO biosynthesis 31.52 11.99 2.63 0.00043 
SOD2 Superoxide dismutase 2 Superoxide detoxification 356.58 135.92 2.62 0.00043 
GPX4 Glutathione peroxidase 4 Prevention of oxidative injury 10.67 4.35 2.45 0.00043 
CXCR4 C-X-C motif chemokine receptor 4 Response to hypoxia, HIF1A pathway 8.27 4.00 2.07 0.00043 
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Figure 1: Interactions among the genes with greatest expression fold change in ARMD vs OA tissue. Genes 
with expression fold change (FC) > 10 in adverse reaction to metal debris (ARMD) vs osteoarthritis (OA) tissue 
were studied with STRING. Genes with no more than 2 interactions are excluded from the graph. Colors of 
the edges: green = activation, blue = binding, black = chemical reaction, red = inhibition, violet = catalysis, 
pink = posttranslational modification, yellow = transcriptional regulation, grey = other interaction. 
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Next, we compared tissue from ARMD reaction to the inflammatory pseudosynovial tissue from a failed MoP 
joint. In these cases, the differences in gene expression were less pronounced: the expression of 16 genes 
was significantly higher (Table 5) and 21 significantly lower (Table 6) in the ARMD reaction. All of these genes 
had a FC of more than 2.0 into either direction. Interestingly, the expression of genes central to myofibroblast 
(AEBP1 and DES) and osteoclast (CCL21, TREM2 and CKB) development was higher in MoP tissue.  
When studying the interactions of the genes which were differentially expressed between ARMD and MoP 
tissues (Figure 2), IL8, NQO1, GSTT1 and HMOX1 were found to occupy central positions in the network, 
suggesting them as potential central regulators of the observed changes. 
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Table 5: Genes with significantly higher expression in ARMD than in MoP tissue. Gene expression levels in 
adverse reaction to metal debris (ARMD) and metal-on-plastic (MoP) samples are listed as reads per kilobase 
million (RPKM) values, and the differences as fold changes (FCs). p-values are adjusted by false discovery rate 
(FDR). 
Gene Name Function 
 RPKM 
(ARMD) 
RPKM 
(MoP) FC adj. p 
RNF170 Ring finger protein 170 
Protein 
ubiquitionation, 
metal ion binding 
 
165.93 3.21 51.77 0.0085 
TRIM25 
Tripartite motif 
containing 25  Immune response 
 
105.81 5.25 20.16 0.0085 
FAM89A 
Family with sequence 
similarity 89 member A ? 
 
167.50 10.55 15.88 0.0085 
SCRIB 
Scribbled planar cell 
polarity protein 
Regulation of cell 
proliferation, 
apoptosis 
 
99.17 8.92 11.12 0.0085 
CPSF1 
Cleavage and 
polyadenylation specific 
factor 1 mRNA processing 
 
125.18 11.94 10.49 0.0085 
STMN1 Stathmin 1  Signal transduction  128.25 19.43 6.60 0.0085 
CCL8 
C-C motif chemokine 
ligand 8 Immune response 
 
25.81 5.36 4.81 0.023 
NOP56 NOP56 ribonucleoprotein  rRNA processing  135.68 32.39 4.19 0.0085 
SLC40A1 
Solute carrier family 40 
member 1  Metal ion transport 
 
168.55 40.79 4.13 0.0085 
NQO1 
NAD(P)H quinone 
dehydrogenase 1 
Redox homeostasis, 
NO biosynthesis 
 
31.52 9.24 3.41 0.0085 
FGFBP2 
Fibroblast growth factor 
binding protein 2 
Tc cell -mediated 
immunity? 
 
62.22 20.04 3.10 0.019 
HMOX1 Heme oxygenase 1  
Redox and metal ion 
homeostasis 
 
523.17 187.11 2.80 0.014 
CLEC5A 
C-type lectin domain 
containing 5A Immune response 
 
29.03 10.55 2.75 0.0085 
IL8 Interleukin 8 
Chemotaxis, Immune 
response 
 
65.98 26.19 2.52 0.014 
EGLN3 
Egl-9 family hypoxia 
inducible factor 3 
Apoptosis, regulation 
of cell proliferation 
 
31.72 12.59 2.52 0.0085 
MGST1 
Microsomal glutathione 
S-transferase 1  Redox homeostasis 
 
57.59 23.96 2.40 0.024 
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Table 6: Genes with significantly lower expression in ARMD than MoP tissue. Gene expression levels in 
adverse reaction to metal debris (ARMD) and metal-on-plastic (MoP) samples are listed as reads per kilobase 
million (RPKM) values, and the differences as fold changes (FCs). p-values are adjusted by false discovery rate 
(FDR). 
  
Gene Name Function 
RPKM 
(ARMD)  
RPKM 
(MoP) FC adj. p 
ACTA1 actin, alpha 1, skeletal muscle Cell structure 5.02 215.18 -42.90 0.0085 
DES desmin  
Cell structure,  
myofibroblast 
development 5.14 117.74 -22.90 0.0085 
HLA-B 
major histocompatibility complex, 
class I, B Immune response 4.44 38.73 -8.72 0.036 
HLA-DRA 
major histocompatibility complex, 
class II, DR alpha Immune response 11.15 78.83 -6.85 0.024 
SERPINA3 serpin family A member 3 Inflammatory response 13.54 70.71 -5.22 0.0085 
CCL21 C-C motif chemokine ligand 21  
T cell chemotaxis, 
osteoclast development 17.69 87.55 -4.95 0.024 
RPS28 ribosomal protein S28 Ribosome component 110.94 406.39 -3.66 0.0085 
CHI3L1 chitinase 3 like 1 (=YKL-40) Inflammatory response 118.76 407.95 -3.44 0.0085 
TPSB2 tryptase beta 2 Proteolysis 17.79 57.86 -3.25 0.047 
PTGES prostaglandin E synthase Inflammatory response 14.36 43.64 -3.04 0.014 
GSTT1 glutathione S-transferase theta 1 Redox homeostasis 27.14 81.94 -3.02 0.023 
MT1E metallothionein Metal ion binding 109.39 319.36 -2.92 0.0085 
RBP4 retinol binding protein 4 Glucose metabolism 93.62 262.29 -2.80 0.0085 
TREM2 
triggering receptor expressed on 
myeloid cells 2 
Immune response,  
osteoclast development 133.31 347.37 -2.61 0.023 
S100A8 S100 calcium binding protein A8 Inflammatory response 145.95 377.50 -2.59 0.024 
AEBP1 AE binding protein 1 
Skeletal system 
development,  
myofibroblast 
development 556.55 1431.68 -2.57 0.024 
CKB creatine kinase B 
Energy homeostasis,  
osteoclast development 25.85 65.07 -2.52 0.24 
TNC tenascin C ECM organization 41.74 97.90 -2.35 0.039 
LPL lipoprotein lipase Lipid metabolism 11.17 27.44 -2.34 0.0141 
GGT5 gamma-glutamyltransferase 5  
Redox homeostasis, 
inflammatory response 23.00 53.56 -2.33 0.019 
COX6B1 cytochrome c oxidase subunit 6B1 Redox metabolism 80.79 185.80 -2.30 0.032 
16 
 
 
 
Figure 2: Interactions among the genes that were differentially expressed in ARMD vs MoP tissue. 
Significantly up- and downregulated genes in ARMD vs OA tissue were studied with STRING. Genes with no 
interactions are excluded from the graph. Colors of the edges: green = activation, blue = binding,  
black = chemical reaction, red = inhibition, violet = catalysis, pink = posttranslational modification,  
yellow = transcriptional regulation, grey = other interaction. 
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Discussion 
When the pseudosynovial ARMD tissue from failed MoM implants was compared to synovial tissue from OA 
joints, a major difference in the gene expression profile was found while the differences between the ARMD 
reaction and the inflammatory reaction around failed MoP joints were less pronounced. Although these 
control tissues, i.e. OA synovium and MoP tissue, are not ideal in all aspects (though probably the best 
available), this study is the first attempt to understand the pathogenesis of the ARMD reaction by applying 
genome-wide expression analysis. 
The list of genes with markedly different expression levels in ARMD and OA samples was found to contain a 
large number of genes involved in inflammatory response, cell proliferation, cellular metabolism and 
apoptosis. The inflammatory genes appear to be dominated by those involved in macrophage and 
lymphocyte-mediated responses, including several cytokines and chemokines, fitting to the current 
conception of the ARMD response [6,13,32]. Accordingly, functional categories (GO terms) included several 
leukocyte signaling pathways such as phospholipase C, PI3K and tyrosine kinase signaling. 
Among the genes with largest differences in expression between ARMD and OA tissue, an interaction 
network centered on clusters of differentiation (CDs) CD2, CD52, CD53 and PRKACB (all strongly upregulated 
in ARMD samples) was discovered in the STRING analysis. Of these, CD2, CD52 and CD53 transduce signals 
from T cell receptors [33,34], and might thus mediate lymphocyte-mediated hypersensitivity reactions to 
metals. The immunoglobulin receptor genes FCGR2A, FCGR2B and FCER1G (also identified in the STRING 
analysis) may also participate in these reactions. However, as far as we know, no previous information about 
the role of any of these genes in ARMD reaction has been published. PRKACB is a serine/threonine protein 
kinase mediating cAMP signaling, with subsequent effects on a wide range of cellular processes, including 
proliferation, differentiation and inflammation [35,36]. Another, smaller network is centered on the pentose 
phosphate shunt -related gene phosphogluconate dehydrogenase (PGD), and includes genes related to 
carbohydrate, lipid and alcohol metabolism. Yet another network was found to be focused on aggrecan 
(ACAN), and included proteoglycan 4 (PRG4), growth and differentiation factor 5 (GDF5) and hyaluronan and 
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proteoglycan link protein 1 (HAPLN1). These genes, traditionally most strongly associated with cartilage 
metabolism, also seem to be expressed at lower levels in other tissues [37]. All of these genes were higher in 
OA synovium than in ARMD tissue, possibly reflecting compensatory increased synthesis of extracellular 
matrix (ECM) components in fibrotic synovial tissue typical for advanced OA [38]. 
The pathogenesis of the ARMD reaction is thought to be driven by metal ions and particles derived from 
MoM implants [8,39]. These implants are made of cobalt-chromium alloys, with other metals such as 
molybdenum and tungsten present in smaller amounts [40]. Due to their very high specific strength and 
corrosion resistance, these alloys were initially thought to be ideal for biomedical applications [41]. However, 
especially when  subjected to large mechanical stress and “edge loading” (head-cup contact patch extending 
over the cup rim), significant amounts of metal particles can be abraded from MoM implants into the 
surrounding tissues [8,42]. Cobalt nanoparticles and Co(II) and Cr(VI) ions appear to be especially toxic, with 
chromium particles and Cr(III) ions only becoming harmful at markedly greater concentrations [43,44]. In the 
literature, the biochemical mechanisms of cobalt-induced toxicity appear to be more comprehensively 
characterized than those of chromium. In addition, cobalt may activate macrophages directly through TLR4 
[17]. It also modifies macrophage phenotype [45] and causes strong oxidative stress [46].  
Cobalt is known to mimic hypoxic conditions in cells, inhibiting the degradation of the transcription factor 
hypoxia-inducible factor 1 alpha (HIF1A) in the proteasome [47] and, accordingly, high expression of hypoxia-
related genes  was observed in ARMD samples. These genes include heme oxygenase 1 (HMOX1), NADPH 
quinone dehydrogenase 1 (NQO1), Egl-9 family hypoxia inducible factor 3 (EGLN3) and superoxide dismutase 
2 (SOD2). HIF1A mRNA levels were not significantly different in either comparison. This was however 
expected, as hypoxia (as well as cobalt) is known to enhance HIF1A expression by inhibiting the degradation 
of the protein, not by affecting on transcription. Accordingly, enhanced HIF1A protein levels have been 
detected in ARMD tissue [18] and in macrophages exposured to cobalt [45]. In conclusion, the present results 
support the hypoxia mimicry hypothesis as a contributing factor in AMRD, but further studies are needed to 
understand the pathogenetic mechanisms in detail.   
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When comparing gene expression in ARMD tissue to that in the inflammatory tissue around failed MoP joints, 
a relatively small number of significantly up- or downregulated genes were identified. This suggests that the 
pathophysiologies of these two reactions hold many similarities.  Indeed, both reactions are thought to be 
particle driven, the other by polyethylene debris and the other by metal debris.  Alarmins, endogenous 
factors that promote noninfective inflammation, may serve as an example of mechanisms involved in both 
responses. As compared to OA samples, ARMD tissue expressed increased levels of S100 calcium-binding 
protein A9 (S100A9), an alarmin that heterodimerizes with S100A8 to form calprotectin [48]. MoP tissue 
expressed S100A9 at equally high levels and in addition, the expression of S100A8 was higher in MoP than in 
ARDM tissue. Alarmin S100A8/S100A9 has been associated with a wide variety of inflammatory conditions, 
from arthritis [49] to lung injury [50]. In previous studies, alarmins in general have been linked to aseptic 
implant loosening [51,52]. Further studies are needed to understand their detailed role in the pathogenesis 
of the response. 
There were also significant differences in the gene expression profiles between ARMD and MoP tissues that 
may provide insights into the mechanisms of the two reaction types. Among the genes upregulated in ARMD 
tissue compared to MoP, there were, perhaps expectedly, several associated with metal ion binding and 
redox homeostasis. These include ring finger protein 170 (RNF170), solute carrier family 40 member 1 
(SLC40A1) and heme oxygenase 1 (HMOX1). The last of these is especially interesting, as it is  a cytoprotective 
factor induced during hypoxia [53]. HMOX1 mediates heme catabolism [54], but also regulates the 
inflammatory response by inhibiting the activation and nuclear translocation of the inflammatory 
transcription factor NF-κB and by enhancing the production of anti-inflammatory cytokines [55]. Along with 
HMOX1, NAD(P)H quinone dehydrogenase (NQO1) and microsomal glutathione S-transferase 1 (MGST1) [56] 
(which were both enhanced in ARMD tissue) are likely compensatory mechanisms to combat the oxidative 
stress induced by metal ions. 
List of the genes, which were higher in MoP than ARMD tissue contained also a number of inflammatory 
genes. These genes appear to be widely expressed by both macrophages and lymphocytes, and thus provide 
20 
 
no specific information about the involvement of these cell types in the reaction. Interestingly, many genes 
stimulating the differentiation and functions of osteoclasts were more highly expressed in MoP tissue 
compared to ARMD. These include C-C motif chemokine ligand 21 (CCL21) [57], triggering receptor expressed 
on myeloid cells 2 (TREM2) [58] and creatine kinase B (CKB) [59]. Osteoclast-mediated bone resorption is a 
known feature of adverse reactions seen in MoM [60] and especially in MoP [22] joints, and polyethylene 
particles have been demonstrated to promote osteoclastic differentiation of mononuclear cells [61]. 
However, the precise roles of the aforementioned factors in these processes remain largely unknown. As far 
as we know, no comprehensive comparative analysis of gene expression in ARMD and MoP reactions has 
previously been published. 
A possible weakness of the present study is that both ARMD and MoP samples were from around failed 
prostheses. This leaves open the possibility that part of the observed changes may be attributed to the 
normal tissue reaction following arthroplasty or to the particle driven reaction leading to implant failure in 
general, rather than specific metal (or plastic) debris evoked toxicity. An ideal control for ARMD tissue would 
have been pseudosynovial tissue from around a normally functioning MoM joint with no signs of ARMD. 
Obtaining such tissue from well-functioning joints is, however, not possible because there is no indication for 
revision surgery. In general, the present results should be interpreted considering these limitations.   
The present results show that there is a widespread difference in gene expression between pseudosynovial 
ARMD tissue and synovial tissue from OA joint. In contrast, differences in gene expression between ARMD 
and MoP tissues were less pronounced and, interestingly, osteolytic genes were among those significantly 
upregulated in MoP tissue. The big picture, based on genome-wide expression analysis, shows that ARMD 
reaction has unique features including up-regulation of genes associated with redox homeostasis, metal ion 
binding and transport, lymphocyte and macrophage activation, cellular metabolism and apoptosis.  
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